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Abstract
Background: Growing evidence suggests that epicardial adipose tissue (EAT) may play a key role in the
pathogenesis and development of coronary artery disease (CAD) by producing several inflammatory adipokines.
Chemerin, a novel adipokine, has been reported to be involved in regulating immune responses and glucolipid
metabolism. Given these properties, chemerin may provide an interesting link between obesity, inflammation and
atherosclerosis. In this study, we sought to determine the relationship of chemerin expression in EAT and the
severity of coronary atherosclerosis in Han Chinese patients.
Methods: Serums and adipose tissue biopsies (epicardial and thoracic subcutaneous) were obtained from CAD
(n = 37) and NCAD (n = 16) patients undergoing elective cardiac surgery. Gensini score was used to assess the
severity of CAD. Serum levels of chemerin, adiponectin and insulin were measured by ELISA. Chemerin protein
expression in adipose tissue was detected by immunohistochemistry. The mRNA levels of chemerin, chemR23,
adiponectin and TNF-alpha in adipose tissue were detected by RT-PCR.
Results: We found that EAT of CAD group showed significantly higher levels of chemerin and TNF-alpha mRNA, and
significantly lower level of adiponectin mRNA than that of NCAD patients. In CAD group, significantly higher levels of
chemerin mRNA and protein were observed in EAT than in paired subcutaneous adipose tissue (SAT), whereas such
significant difference was not found in NCAD group. Chemerin mRNA expression in EAT was positively correlated with
Gensini score (r = 0.365, P < 0.05), moreover, this correlation remained statistically significant (r = 0.357, P < 0.05) after
adjusting for age, gender, BMI and waist circumference. Chemerin mRNA expression in EAT was also positively
correlated with BMI (r = 0.305, P < 0.05), waist circumference (r = 0.384, P < 0.01), fasting blood glucose (r = 0.334, P <
0.05) and negatively correlated with adiponectin mRNA expression in EAT (r = -0.322, P < 0.05). However, there were no
significant differences in the serum levels of chemerin or adiponectin between the two groups. Likewise, neither serum
chemerin nor serum adiponectin was associated with Gensini score (P > 0.05).
Conclusions: The expressions of chemerin mRNA and protein are significantly higher in EAT from patients with
CAD in Han Chinese patients. Furthermore, the severity of coronary atherosclerosis is positive correlated with the
level of chemerin mRNA in EAT rather than its circulating level.
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Currently, obesity and accumulation of visceral adipose
tissue have been considered as the important risk factors
for metabolic syndrome and coronary artery disease (CAD)
[1]. Adipose tissue is now recognized as an active endo-
crine organ expressing and secreting several inflammatory
mediators and cytokines, also known as adipokines, which
participate in the development of atherosclerosis [2].
Epicardial adipose tissue (EAT) is a type of visceral fat [3].
Most recently, particular research interests have focused
on EAT due to its close proximity to coronary arteries and
the plausibility that the adipokines derived from it may
have direct effects on each layer of the coronary wall via
paracrine and vasocrine pathways [4]. Previous studies
have revealed that atherosclerotic intimal lesions are not
seen in the coronary arterial segments absent of EAT or
covered by myocardium [5], suggesting EAT may play a
role in the development of coronary atherosclerosis. Subse-
quent studies have demonstrated that significantly lower
level of adiponectin and significantly higher levels of
inflammatory cytokines exist in the EAT of patients with
CAD [6,7]. Recently, some evidence also proves that CAD
is associated with increased chemokines production by
EAT [8-11]. In addition, infiltration of macrophages are
increased [12] and inflammatory pathways mediated by
nuclear factor-B and Janus kinase (JNK) are activated in
EAT in the presence of CAD [13]. All these data above
suggest EAT, due to its regional pro-inflammatory proper-
ties, may play an important role in the pathogenesis of
CAD.
Chemerin, also known as tazarotene-induced gene 2
(TIG2) or retinoic acid receptor responder 2
(RARRES2), functions as a chemotactic protein that
binds to the G protein-coupled receptor, CMKLR1
(chemR23), in humans [14]. Recently, it has been identi-
fied as a novel adipokine owing to its high expression
level in white adipocytes. Chemerin has been reported
to be involved in modulating immune responses and
glucolipid metabolism. Furthermore, some studies have
shown the strong association of serum chemerin level
with markers of inflammation and components of the
metabolic syndrome [15]. Therefore, the double role of
chemerin in inflammation and metabolism may provide
an interesting link between obesity, inflammation and
atherosclerosis. However, the association of chemerin
with atherosclerosis has not yet been proved. In this
study, we sought to determine the relationship of che-
merin expression in human EAT and the severity of cor-
onary atherosclerosis.
Methods
Subjects
Between October 2009 and March 2010, a total of 53
Han Chinese patients who underwent elective cardiac
surgery were enrolled in the study. Exclusion criteria
included non ischemic cardiomyopathy, liver or renal
failure, neoplastic disease, thyroid or adrenal gland dis-
ease, acute infectious disease, the aged (> 80 years) or
patients taking corticosteroids, oral contraceptives, or
psychotropic drugs. Patients were divided into CAD
group and NCAD group according to the results of
selective coronary angiography. CAD was defined as the
presence of stenoses of greater than 50% of the luminal
diameter for at least one of the three major coronary
arteries. All CAD patients underwent elective coronary
artery bypass graft (CABG) surgery. All NCAD patients
received elective open-heart surgery for valvular replace-
ment or atrial septal defect closure. These patients had
no clinical signs of CAD and did not show significant
coronary stenoses (≥50%) in the pre-operative coronary
angiographic examination.
This study was approved by the ethics committee of
Beijing Anzhen Hospital of Capital Medical University.
This study complied with the declaration of Helsinki
with the written informed consent obtained from all
subjects prior to enrolment.
Clinical data collection
Clinical data were obtained upon admission to hospital
before surgery. Demographic data, medical history, and
medications being used before surgery were recorded. In
addition, height, body weight, waist circumference and
blood pressure were measured. Then body mass index
(BMI) was calculated as weight (kg) divided by square of
height (m
2).
Gensini score assessment
Angiographic analyses were carried out by two experi-
enced interventional cardiologists who were blinded to
the study protocol according to the result of coronary
angiography within six months prior to surgery. Then
Gensini score was calculated to assess the severity of
coronary atherosclerosis according to the method
described in the literature [16].
Blood samples detection
Peripheral venous blood samples were collected after over-
night fasting on the day after admission, and serum glu-
cose, lipid profiles, high sensitivity C-reactive protein
(hsCRP), insulin and hemoglobin A1C (HbA1C) were ana-
lyzed in central laboratory of Beijing Anzhen Hospital.
Insulin sensitivity was estimated by homeostasis model
assessment of insulin resistance (HOMA-IR) calculated as
fasting glucose (mmol/L) × fasting insulin (μU/mL)/22.5.
Central venous blood was drawn before cardiopulmon-
ary bypass during the operation. Then serum was stored
in aliquots at -80°C until being analyzed. Serum levels
of chemerin and adiponectin were determined by
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assay (ELISA) kits (Adipobiotech, Beijing, China).
Adipose tissue acquisition
Adipose biopsy samples were obtained prior to the initia-
tion of cardiopulmonary bypass from areas that had not
previously been injured mechanically or cauterized. EAT
biopsies (average 0.5 g) were taken near the proximal right
coronary artery, and subcutaneous adipose tissue (SAT)
samples were collected from the site of the chest incision.
The specimens were rinsed with normal saline and divided
into two portions. After removal of visible blood vessels,
one portion was frozen immediately in liquid nitrogen and
stored at -80°C for RNA isolation, another was immersed
in neutralized formalin for immunohistochemical analysis.
Immunohistochemistry
Paraffin-embedded tissue sections were deparaffined and
rehydrated in descending grades of alcohol and stained
with hematoxylin and eosin. Selected serial sections were
subjected to immunohistochemistry with the Histostain-
Plus Kit LAB-SA Detection System (Invitrogen, USA)
according to the manufacturer’s protocol. Briefly, sections
were incubated in 3% H2O2 for 20 minutes followed by
blocking with normal goat serum. After they were washed
in PBS, sections were incubated with primary antibodies
(Chemerin, 1:200, Adipobiotech, Beijing, China) overnight
at 4°C in a moisture chamber. Afterward, the slides were
incubated with biotinylated secondary antibodies for
10~15 minutes followed by avidin-biotin for 15 minutes.
Sections were then exposed to DAB and counterstained
with hematoxylin. Negative controls were carried out
omitting the primary antibody. Brightfield images were
observed with a light microscope and digital images were
recorded. Positive staining for chemerin was brown.
Expression of chemerin was quantified by calculating the
integrated optical density (IOD) of positive staining tissue
via Image-pro plus software. The IOD of each tissue sec-
tion was calculated from eight different 400 magnified
fields.
RNA extraction and Reverse Transcription-Polymerase
Chain Reaction (RT-PCR)
Total RNA was extracted from adipose tissue samples
using Trizol reagent (Invitrogen, USA). The concentration
and purity of isolated RNA were assessed by measuring
the optical density at 260 nm (OD260) and 280 nm
(OD280), and the integrity of RNA was also determined
by visualisation of 18S and 28S ribosomal bands. 1 μgo f
RNA from each sample was reverse transcribed using
oligo(dT)15 and M-MLV Reverse Transcriptase (Promega,
USA), according to the manufacturer’s instructions. An
aliquot of 2 μL of the resulting cDNA was used for semi-
quantitative PCR. PCR was carried out in a volume of
25 μL containing 12.5 μL2×P C R - M i x ,1μL1 0μmol/L
each primer, and sterile water. The primers were designed
using the Primer 5.0 software program, with their sites
spanning introns, so quantitation of the reaction was not
affected by the presence of genomic DNA. The primers
used for amplification were shown in Table 1. Apart from
the optimal annealing temperature and number of cycles
of amplification, other conditions were the same in all
PCR reactions. PCR was performed under the following
conditions: 3 minutes for an initial denaturation at 94°C,
followed by different cycles (30 s for denaturation at 94°C,
30 s for annealing and 50 s for extension at 72°C), and 5
minutes for a final extension at 72°C. The number of PCR
cycles in each system was chosen within linear phase in
our preliminary trial to ensure the accuracy of semiquanti-
tative analysis. A 5 μl aliquot of PCR products was then
analyzed using 1.5% agarose gel electrophoresis. Band
intensity for the target gene was quantified by densitome-
try using Scion Image software and normalized to b-actin
mRNA level to determine relative mRNA expression of
the target gene.
Statistical analysis
Variables such as serum adiponectin, hsCRP and trigly-
ceride with skewed distribution were log transformed.
Continuous variables with normal distribution were
expressed as mean ± SD, means were compared by paired
or unpaired Student’s t-test, as appropriate. Whereas for
data with skewed distribution, Mann-Whitney U test was
used. Categorical variables were presented as percentages
and were analyzed by Chi-squared test. Associations
between the levels of adipokines in EAT and serum and
clinical variables were determined with the Pearson or
Spearman correlation coefficients. Partial correlation ana-
lysis was performed to evaluate adjusted association
between chemerin mRNA level in EAT and Gensini score.
All statistical analyses were performed using SPSS 16.0
software, the P-value < 0.05 was considered statistically
significant.
Results
Patient characteristics
The baseline characteristics of the two groups were shown
in Table 2. In the CAD group (n = 37), 30 were men, and
mean age was 59.1 ± 8.0 years. In the NCAD group (n =
16), 12 were men, and mean age was 54.3 ± 9.4 years. As
expected, the majority of patients undergoing CABG sur-
gery had multi-vessel lesions, moreover, obesity and
hypertension were more prevalent in the CAD group than
in the NCAD group. There were no significant difference
in age, gender, diabetes, left ventricular ejection fraction,
blood pressure, triglycerides, total cholesterol, LDL choles-
terol, HbA1C, serum creatinine, urea nitrogen, uric acid,
medications treatment such as angiotensin converting
Gao et al. Cardiovascular Diabetology 2011, 10:87
http://www.cardiab.com/content/10/1/87
Page 3 of 9enzyme inhibitors/angiotensin II type 1 receptor blockers
(ACEIs/ARBs), oral hypoglyceimic agents, insulin and
antibiotics between the two groups.
However, patients in the CAD group presented higher
levels of fasting glucose, HOMA-IR, hsCRP, and lower
HDL cholesterol level compared to those in the NCAD
group. As for current medications therapy, aspirin,
nitrates, beta-blockers, statins, and calcium channel block-
ers were prescribed more often in the CAD patients than
in the NCAD patients.
Immunohistochemical analysis
We performed immunohistochemistry to illustrate che-
merin expression in adipose tissue. EAT and SAT samples
were collected randomly from the CAD group (n = 6) and
the NCAD group (n = 6), respectively. Figure 1A showed
the representative slides of EAT and SAT from one patient
with CAD (Figure 1A-a and 1A-b) and one without CAD
(Figure 1A-c and 1A-d). Immunohistochemical staining
revealed that chemerin was expressed in both EAT and
SAT of the two groups. Furthermore, as shown in Figure
1B, quantitative analysis of immunohistochemistry
revealed that the amounts of chemerin protein in EAT
were higher in the patients with CAD than those without
CAD (70128.28 ± 13068.83 vs. 52312.03 ± 9899.90, P <
0.05). For the CAD group, significantly higher level of che-
merin protein was found in EAT than in SAT (70128.28 ±
13068.83 vs. 42942.04 ± 15460.67, P < 0.01), whereas no
significant difference was found between EAT and SAT in
the NCAD group (52312.03 ± 9899.90 vs. 50533.71 ±
17289.54, P = 0.871).
EAT adipokines mRNA expression between CAD group
and NCAD group
As illustrated in Figure 2, we found significantly higher
levels of chemerin, TNF-a mRNA and significantly lower
level of adiponectin mRNA in EAT of CAD group com-
pared to that of NCAD group, whereas the mRNA
expression of chemR23 in EAT did not show significant
difference between the two groups (chemerin 0.94 ± 0.17
vs. 0.78 ± 0.21, P <0 . 0 1 ;T N F - a 0.36 ± 0.34 vs. 0.15 ±
0.19, P < 0.01; adiponectin 0.71 ± 0.15 vs. 0.83 ± 0.12, P <
0.01; chemR23 0.83 ± 0.45 vs. 0.62 ± 0.45, P = 0.140).
Chemerin mRNA expression between EAT and SAT
As for the comparison of paired EAT and SAT, 3 SAT
samples of CAD group were excluded from the analysis
due to insufficient adipose tissue biopsy samples or being
damaged during the operation. As shown in Figure 3, in
the CAD group, significantly higher level of chemerin
mRNA was observed in EAT than in paired SAT (0.94 ±
0.17 vs. 0.84 ± 0.28, P < 0.05), whereas chemerin mRNA
level did not seem to differ between the two adipose
depots in the NCAD group (0.78 ± 0.21 vs. 0.82 ± 0.37,
P > 0.05). Moreover, chemerin mRNA expression in SAT
of CAD group was comparable with that in SAT of
NCAD group (0.84 ± 0.28 vs. 0.82 ± 0.37, P > 0.05).
Association of EAT chemerin mRNA expression with
clinical parameters
Chemerin mRNA expression in EAT was positively cor-
related with Gensini score (r = 0.365, P < 0.05). Further-
more, this correlation revealed by partial correlation
analysis remained statistically significant (r = 0.357, P <
0.05) even after adjusting for age, gender, BMI and waist
circumference. Chemerin mRNA expression in EAT was
also found to be positively correlated with BMI (r =
0.305, P < 0.05), waist circumference (r = 0.384, P <
0.01), fasting glucose (r = 0.334, P < 0.05), chemR23
mRNA expression in EAT (r = 0.349, P < 0.05) and nega-
tively correlated with adiponectin mRNA expression in
EAT (r = -0.322, P < 0.05). However, no association was
observed between chemerin mRNA expression in EAT
and TNF-a mRNA expression in EAT (P > 0.05).
Serum adipokines analysis
The serum samples of 33 CAD patients and 11 NCAD
patients met the criteria for analysis. The two groups
Table 1 Primers for RT-PCR reaction
Gene title Accession number Primer sequence Cycle Ta (°C) Product (bp)
Chemerin NM_002889.3 F: 5’-GAAGAAACCCGAGTGCAAAG-3’ 28 56 229
R: 5’-CTTGGAGAAGGCGAACTGTC-3’
ChemR23 NM_001142343.1 F: 5’-CTCCCAATCCATATCACCTA-3’ 32 58 543
R: 5’-GCAGAGGAAGAAGGTAATGA-3’
Adiponectin NM_001177800.1 F: 5’-CTCCTCCTCACTTCCATTCTG-3’ 35 58 310
R: 5’-TTTCACCGATGTCTCCCTTA-3’
TNF-a NM_000594.2 F: 5’-TTCTGCCTGCTGCACTTTGGA-3’ 40 60 592
R: 5’-GGCGTTTGGGAAGGTTGGATG-3’
b-actin NM_001101.3 F: 5’-AGGTCATCACCATTGGCAAT-3’ 26 58 357
R: 5’-ACTCGTCATACTCCTGCTTG-3’
Abbreviations: TNF-a, tumor necrosis factor-a; Ta, annealing temperature.
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nificant differences in the serum levels of chemerin or
adiponectin between the two groups (chemerin 118.13 ±
32.02 ng/ml vs. 99.60 ± 28.66 ng/ml, P = 0.096; adipo-
nectin 4.90 ± 1.39 μg/ml vs. 5.87 ± 1.52 μg/ml, P =
0.155). Correlation analysis revealed that serum che-
merin concentration was positively correlated with BMI
(r = 0.323, P < 0.05), waist circumference (r = 0.398, P <
0.01), HOMA-IR (r = 0.299, P < 0.05) and hsCRP (r =
0.340, P < 0.05). However, neither serum chemerin (r =
0.295, P = 0.120) nor serum adiponectin (r = -0.328, P =
0.083) level was found to be associated with Gensini
score. Also, there was no statistically significant correla-
tion between serum chemerin level and its expression
level in EAT (P > 0.05).
Discussion
In the present study, we found that EAT of CAD group
showed significantly higher levels of chemerin mRNA
and protein when compared with that of NCAD patients
in Han Chinese patients. Moreover, chemerin mRNA
expression in EAT was positively correlated with the
severity of coronary atherosclerosis. However, there was
no significant difference in the serum level of chemerin
between the two groups. Likewise, no statistically signifi-
cant association was found between serum chemerin
level and coronary atherosclerosis. Spiroglou et al. have
reported a positive correlation between coronary athero-
sclerosis and chemerin expression in pericoronary adi-
pose tissue of autopsy cases [17], but their research was
not a case-control study, and whether the expression of
Table 2 Baseline characteristics of CAD and NCAD groups before surgery
CAD (n = 37) NCAD (n = 16) P
Age (years) 59.1 ± 8.0 54.3 ± 9.4 NS
Male (%) 30 (81.1) 12 (75.0) NS
Hypertension (%) 27 (73.0) 3 (18.8) < 0.001
T2 DM (%) 11 (29.7) 1 (6.2) NS
BMI (kg/m
2) 27.1 ± 3.4 24.3 ± 2.6 0.004
Waist circumference (cm) 94.7 ± 9.2 85.5 ± 9.8 0.002
LVEF (%) 56.2 ± 10.1 60.1 ± 8.1 NS
Systolic blood pressure (mmHg) 129.3 ± 20.7 127.1 ± 19.5 NS
Diastolic blood pressure (mmHg) 78.1 ± 12.4 79 ± 14.0 NS
Aspirin (%) 16 (43.2) 0 (0) 0.005
Nitrates (%) 37 (100) 0 (0) < 0.001
ACEIs/ARBs (%) 22 (59.5) 9 (56.2) NS
Statins (%) 25 (67.6) 0 (0) < 0.001
b-blockers (%) 35 (94.6) 3 (18.8) < 0.001
Calcium channel blockers (%) 13 (35.1) 0 (0) 0.017
Insulin (%) 5 (13.5) 1 (6.2) NS
Oral hypoglyceimic agents (%) 9 (24.3) 1 (6.2) NS
Diuretics (%) 2 (5.4) 16 (100) < 0.001
Antibiotics (%) 6 (16.2) 4 (25.0) NS
Fasting glucose (mmol/L) 6.08 (5.25, 7.45) 5.19 (4.86, 5.51) 0.002
HbA1C (%) 6.3 ± 0.8 6.0 ± 0.6 NS
Fasting insulin (μU/mL) 4.67 (2.43, 45.75) 2.27 (1.77, 3.06) 0.031
HOMA-IR 1.43 (0.69, 1.32) 0.53 (0.44, 0.68) 0.013
Total cholesterol (mmol/L) 4.44 ± 1.00 4.83 ± 0.73 NS
HDL-C (mmol/L) 1.07 ± 0.24 1.25 ± 0.22 0.014
LDL-C (mmol/L) 2.68 ± 0.81 2.89 ± 0.53 NS
Triglycerides (mmol/L) 1.88 ± 1.09 1.77 ± 1.49 NS
Urea nitrogen (mmol/L) 6.82 ± 2.58 7.67 ± 2.46 NS
Serum creatinine (μmol/L) 89.9 ± 21.3 83.5 ± 20.1 NS
Uric acid (μmol/L) 380.2 ± 111.1 393.3 ± 96.8 NS
hsCRP (mg/L) 1.95 (0.98, 6.75) 1.07 (0.51, 1.66) 0.003
Data are presented as mean ± SD, median (lower quartile, upper quartile), or number (%), P value represents CAD group vs. NCAD group. Abbreviations: CAD,
coronary artery disease; T2DM, type 2 diabetes; BMI: body mass index; LVEF, left ventricular ejection fraction; ACEIs: angiotensin converting enzyme inhibitors;
ARBs: angiotensin II type 1 receptor blockers; HbA1C, hemoglobin A1C; HOMA-IR: homeostasis model assessment of insulin resistance; HDL-C, high-density
lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol; hsCRP, high sensitivity C-reactive protein; NS, non-significance.
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fered or by death were uncertain. Our study excluded the
established confounding factors which might influence
the expression of chemerin and demonstrated the corre-
lation of chemerin expression in EAT and the coronary
atherosclerosis in Han Chinese patients, which was con-
sistent with the results of the study by Spiroglou et al.
Another study found serum chemerin level was not asso-
ciated with coronary atherosclerotic plaque morphology
as determined by computed tomography-angiography in
patients with stable chest pain [15], which was consistent
with our findings. Most recently, Becker and his co-work-
ers reported that long-term overexpression of chemerin
did not significantly affect extent of atherosclerotic lesion
area in vivo [18]. Taken together, all these studies sug-
gested that locally produced chemerin by EAT rather
than its circulating level might affect the atherosclerotic
process.
As expected, we observed that both chemerin mRNA
expression in EAT and its serum level were positively
correlated with indexes of obesity (BMI and waist cir-
cumference). The present findings were to some extent
supported by the fact that significantly higher chemerin
secretion from adipose tissue [19] as well as its circulat-
ing level in obese patients [20] and significantly decreased
serum chemerin level with weight loss after bariatric sur-
gery [21]. With regard to the close association of che-
merin and obesity, a plausible interpretation was that
chronic low-grade inflammation that occurred in obesity
might promote chemerin production by adipocytes
[22,23]. On the other hand, chemerin could also promote
the differentiation of preadipocytes in vitro [24], thereby
might contribute to obesity.
Previous studies have reported that chemerin mRNA
expression in EAT was associated with the indexes of obe-
sity, and obesity has been considered as one of the most
important risk factors for CAD. In order to exclude the
effects of these potential confounders on coronary athero-
sclerosis, we performed partial correlation analysis and
observed the correlation between chemerin mRNA
expression in EAT and coronary atherosclerosis remained
statistically significant after adjusting for age, gender, BMI
and waist circumference. The association between EAT-
derived chemerin and coronary atherosclerosis could be
Figure 1 Immunohistochemical analysis for chemerin in EAT and SAT. (A): the representative slides of EAT and SAT are from a patient with
CAD (a and b) and a patient without CAD (c and d) separately (magnified × 400). Negative control with omission of primary antibody (e). (B):
the result of quantitative analysis of immunohistochemistry for chemerin in EAT and SAT of the two groups (CAD group, n = 6; NCAD group,
n = 6). * indicates P < 0.05, EAT of CAD group vs. EAT of NCAD group. ** indicates P < 0.01 as determined by paired t-test, EAT of CAD group
vs. SAT of CAD group. Abbreviations: EAT, epicardial adipose tissue; SAT, subcutaneous adipose tissue; IOD, integrated optical density.
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increased levels of inflammatory cytokines (TNF-a and
IL-1b) in circulating and coronary blood of patients with
CAD could up-regulate chemerin in adjacent EAT via
“inside to outside” signaling [22,23]. On the other hand, as
in vitro studies indicated, chemerin could recruit and acti-
vate macrophages [25], promote cholesterol uptake [26]
and induce endothelial angiogenesis in vitro [27], so we
supposed that in vivo chemerin secreted by EAT could
also be transported downstream to interact with each
layer of the coronary wall through “outside to inside” sig-
naling [28], thus participating in several stages of the cor-
onary atherosclerotic process: chemotaxis, foam cell
formation and plaque destabilization. Hence we hypothe-
sized that EAT-derived chemerin and coronary athero-
sclerosis might interact with each other. However, because
our research was a cross-sectional study, we could not
draw any causal conclusions about their association. The
direct effects of EAT-derived chemerin on coronary ather-
osclerosis in vivo still needs to be further ascertained.
Previous studies have highlighted that significantly
lower expression of adiponectin [7,29] and significantly
higher expression of chemokine (MCP-1) and several
inflammatory cytokines (TNF-a,I L - 1 b,I L - 6 )w e r e
observed in EAT than in SAT [28]. In our study, we
also found chemerin mRNA expression was significantly
higher in EAT compared to paired SAT for CAD
patients, whereas for NCAD patients, no significant dif-
ference was found between the two adipose depots. This
result indicated that EAT might play a more significant
role in the pathogenesis of coronary atherosclerosis than
SAT.
We also concluded that EAT of CAD group showed
significantly lower expression of adiponectin and signifi-
cantly higher expression of TNF-a when compared with
that of NCAD patients. This finding was confirmed by
previous studies [6,7], suggested the pro- and anti-
inflammatory unbalance in EAT of patients with CAD.
In addition, we observed a negative correlation between
chemerin mRNA expression in EAT and adiponectin
mRNA expression in EAT, which was consistent with
the correlation of their protein levels [17].
Just as Mazurek et al. [28] illustrated that local inflam-
matory burden in EAT did not correlate with their circu-
lating concentrations, in the present study, no association
was found between serum chemerin level and its expres-
sion level in EAT. The following reasons could be put
forward to explain this phenomenon. First, we merely
detected chemerin at the transcription level which might
not reflect the level of its protein translation and secre-
tion. Second, EAT is only 1% of total fat mass, apart from
EAT, other adipose depots as well as liver were also
important sources of circulating chemerin level [24,30].
Therefore, the contribution of EAT-derived chemerin to
its systemic level might be negligible.
Several limitations of the present study should be con-
sidered. First, owing to the restriction of the amount of
EAT biopsy samples, we merely detected chemerin
mRNA and protein in EAT. It might have been useful to
measure the level of chemerin secretion from EAT. Sec-
ond, although the sample size of our study was relatively
large in comparison with other similar studies on EAT,
we still could not carry out multivariate analysis to
further clarify whether overexpression of chemerin in
Figure 2 The mRNA expression levels of adipokines in EAT between the two groups. (A): the result of agarose gel electrophoresis of PCR
products in EAT. (B): the result of relative mRNA levels of chemerin, chemR23, adiponectin and TNF-a in EAT of the two groups (CAD group,
n = 37; NCAD group, n = 16). ** indicates P < 0.01, CAD group vs. NCAD group. Abbreviations: a.u., arbitrary units.
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sclerosis. Finally, for serum analyses, the small serum
sample size as well as the absence of serums of normal
controls might have prevented us from achieving statisti-
cally significant associations.
Conclusions
In conclusion, our study demonstrates that the expres-
sions of chemerin mRNA and protein are significantly
higher in EAT from patients with CAD in Han Chinese
patients. Furthermore, the severity of coronary athero-
sclerosis is associated with the level of chemerin mRNA
in EAT rather than its circulating level. Further studies
aiming at exploring the direct effects of EAT-derived
chemerin on coronary atherosclerosis and its related
molecular mechanisms will provide a novel target for
the prevention and treatment of CAD.
Acknowledgements
This study was supported by National Natural Science Foundation of China
(No. 81100600) and the Funds of The Scientific Cooperation of Basic
Medicine and Clinical Medicine of Capital Medical University (No.10JL54). We
thank the cardiac surgeons Jinhua Li, Jingwei Li, Zhiqiang Luo, Liang Zhang,
Ping Li, Lili Xu and Tao Bai at Beijing Anzhen Hospital for their assistance in
collecting adipose biopsy samples, and Qiang Shi for his assistance in
revising the manuscript. Additionally, we also thank the patient volunteers
for their participation.
Figure 3 The mRNA expression level of chemerin between EAT and SAT. (A): the result of agarose gel electrophoresis of PCR products in
EAT and SAT. (B): the scattered graph of relative mRNA levels of chemerin in EAT and SAT of the two groups (CAD group, n = 34; NCAD group,
n = 16).
Gao et al. Cardiovascular Diabetology 2011, 10:87
http://www.cardiab.com/content/10/1/87
Page 8 of 9Author details
1Department of Endocrinology, The Key Laboratory of Remodeling-related
Cardiovascular Diseases, Beijing Anzhen Hospital, Capital Medical University,
Ministry of Education, Beijing, 100029, China.
2Department of Special Care,
Beijing Anzhen Hospital, Capital Medical University, Beijing, 100029, China.
3Department of Endocrinology, Peking Union Medical College Hospital,
Peking Union Medical College, Chinese Academy of Medical Sciences,
Beijing, 100730, China.
4Department of Cardiac Surgery, Beijing Anzhen
Hospital, Capital Medical University, Beijing, 100029, China.
Authors’ contributions
XG carried out the molecular genetic studies and serum detection,
participated in the design of the study and drafted the manuscript. FZ
carried out the immunoassays. XG, FZ and XZ involved in the acquisition of
data as well as analysis and interpretation of data. YL and FG collected
adipose biopsy samples and serum samples. XG performed the statistical
analysis. HT and LW have been involved in revising the manuscript critically
for important intellectual content. HT, SM and FG conceived of the study,
and participated in its design and coordination. All authors have read and
approved the final manuscript.
Competing interests
The authors declare that they have no competing interests.
Received: 16 July 2011 Accepted: 7 October 2011
Published: 7 October 2011
References
1. Mathieu P, Pibarot P, Larose E, Poirier P, Marette A, Després JP: Visceral
obesity and the heart. Int J Biochem Cell Biol 2008, 40:821-836.
2. Fischer-Posovszky P, Wabitsch M, Hochberg Z: Endocrinology of adipose
tissue - an update. Horm Metab Res 2007, 39:314-321.
3. Iacobellis G, Corradi D, Sharma AM: Epicardial adipose tissue: anatomic,
biomolecular and clinical relationships with the heart. Nat Clin Pract
Cardiovasc Med 2005, 2:536-543.
4. Yudkin JS: Inflammation, obesity and the metabolic syndrome. Horm
metab Res 2007, 39:707-709.
5. Ishii T, Asuwa N, Masuda S, Ishikawa Y: The effects of a myocardial bridge
on coronary atherosclerosis and ischaemia. J Pathol 1998, 185:4-9.
6. Eiras S, Teijeira-Fernández E, Shamagian LG, Fernandez AL, Vazquez-
Boquete A, Gonzalez-Juanatey JR: Extension of coronary artery disease is
associated with increased IL-6 and decreased adiponectin gene
expression in epicardial adipose tissue. Cytokine 2008, 43:174-180.
7. Zhou Y, Wei Y, Wang L, Wang X, Du X, Sun Z, Dong N, Chen X: Decreased
adiponectin and increased inflammation expression in epicardial
adipose tissue in coronary artery disease. Cardiovasc Diabetol 2011, 10:2.
8. Henrichot E, Juge-Aubry CE, Pernin A, Pache JC, Velebit V, Dayer JM,
Meda P, Chizzolini C, Meier CA: Production of chemokines by perivascular
adipose tissue: a role in the pathogenesis of atherosclerosis? Arterioscler
Thromb Vasc Biol 2005, 25:2594-2599.
9. Shibasaki I, Nishikimi T, Mochizuki Y, Yamada Y, Yoshitatsu M, Inoue Y,
Kuwata T, Ogawa H, Tsuchiya G, Ishimitsu T, Fukuda H: Greater expression
of inflammatory cytokines, adrenomedullin, and natriuretic peptide
receptor-C in epicardial adipose tissue in coronary artery disease. Regul
Pept 2010, 165:210-217.
10. Karastergiou K, Evans I, Ogston N, Miheisi N, Nair D, Kaski JC, Jahangiri M,
Mohamed-Ali V: Epicardial adipokines in obesity and coronary artery
disease induce atherogenic changes in monocytes and endothelial cells.
Arterioscler Thromb Vasc Biol 2010, 30:1340-1346.
11. Madani R, Karastergiou K, Ogston NC, Miheisi N, Bhome R, Haloob N,
Tan GD, Karpe F, Malone-Lee J, Hashemi M, Jahangiri M, Mohamed-Ali V:
RANTES release by human adipose tissue in vivo and evidence for
depot-specific differences. Am J Physiol Endocrinol Metab 2009, 296:
E1262-E1268.
12. Baker AR, Silva NF, Quinn DW, Harte AL, Pagano D, Bonser RS, Kumar S,
McTernan PG: Human epicardial adipose tissue expresses a pathogenic
profile of adipocytokines in patients with cardiovascular disease.
Cardiovasc Diabetol 2006, 5:1.
13. Baker AR, Harte AL, Howell N, Pritlove DC, Ranasinghe AM, da Silva NF,
Youssef EM, Khunti K, Davies MJ, Bonser RS, Kumar S, Pagano D,
McTernan PG: Epicardial adipose tissue as a source of NFκB and JNK
mediated inflammation in patients with coronary artery disease. J Clin
Endocrinol Metab 2009, 94:261-267.
14. Wittamer V, Franssen JD, Vulcano M, Mirjolet JF, Le Poul E, Migeotte I,
Brézillon S, Tyldesley R, Blanpain C, Detheux M, Mantovani A, Sozzani S,
Vassart G, Parmentier M, Communi D: Specific recruitment of antigen-
presenting cells by chemerin, a novel processed ligand from human
inflammatory fluids. J Exp Med 2003, 198:977-985.
15. Lehrke M, Becker A, Greif M, Stark R, Laubender RP, von Ziegler F,
Lebherz C, Tittus J, Reiser M, Becker C, Göke B, Leber AW, Parhofer KG,
Broedl UC: Chemerin is associated with markers of inflammation and
components of the metabolic syndrome but does not predict coronary
atherosclerosis. Eur J Endocrinol 2009, 161:339-344.
16. Gensini GG: A more meaningful scoring system for determining the
severity of coronary heart disease. Am J Cardiol 1983, 51:606.
17. Spiroglou SG, Kostopoulos CG, Varakis JN, Papadaki HH: Adipokines in
periaortic and epicardial adipose tissue: differential expression and
relation to atherosclerosis. J Atheroscler Thromb 2010, 17:115-130.
18. Becker M, Rabe K, Lebherz C, Zugwurst J, Göke B, Parhofer KG, Lehrke M,
Broedl UC: Expression of human chemerin induces insulin resistance in
the skeletal muscle but does not affect weight, lipid levels, and
atherosclerosis in LDL receptor knockout mice on high-fat diet. Diabetes
2010, 59:2898-2903.
19. Sell H, Laurencikiene J, Taube A, Eckardt K, Cramer A, Horrighs A, Arner P,
Eckel J: Chemerin is a novel adipocyte-derived factor inducing insulin
resistance in primary human skeletal muscle cells. Diabetes 2009,
58:2731-2740.
20. Bozaoglu K, Bolton K, McMillan J, Zimmet P, Jowett J, Collier G, Walder K,
Segal D: Chemerin is a novel adipokine associated with obesity and
metabolic syndrome. Endocrinology 2007, 148:4687-4694.
21. Ress C, Tschoner A, Engl J, Klaus A, Tilg H, Ebenbichler CF, Patsch JR,
Kaser S: Effect of bariatric surgery on circulating chemerin levels. Eur J
Clin Invest 2010, 40:277-280.
22. Parlee SD, Ernst MC, Muruganandan S, Sinal CJ, Goralski KB: Serum
chemerin levels vary with time of day and are modified by obesity and
tumor necrosis factor-alpha. Endocrinology 2010, 151:2590-2602.
23. Kralisch S, Weise S, Sommer G, Lipfert J, Lossner U, Bluher M, Stumvoll M,
Fasshauer M: Interleukin-1beta induces the novel adipokine chemerin in
adipocytes in vitro. Regul Pept 2009, 154:102-106.
24. Goralski KB, McCarthy TC, Hanniman EA, Zabel BA, Butcher EC, Parlee SD,
Muruganandan S, Sinal CJ: Chemerin, a novel adipokine that regulates
adipogenesis and adipocyte metabolism. J Biol Chem 2007,
282:28175-28188.
25. Wittamer V, Bondue B, Guillabert A, Vassart G, Parmentier M, Communi D:
Neutrophil-mediated maturation of chemerin: a link between innate and
adaptive immunity. J Immunol 2005, 175:487-493.
26. McCarthy TC, Zuniga LA, Zabel BA, Butcher EC, Sinal CJ: The novel
adipokine chemerin significantly increases cholesterol uptake in human
macrophages [Abstract]. FASEB J 2008, 22:948, .
27. Kaur J, Adya R, Tan BK, Chen J, Randeva HS: Identification of chemerin
receptor (ChemR23) in human endothelial cells: Chemerin-induced
endothelial angiogenesis. Biochem Biophys Res Commun 2010,
391:1762-1768.
28. Mazurek T, Zhang L, Zalewski A, Mannion JD, Diehl JT, Arafat H, Sarov-
Blat L, O’Brien S, Keiper EA, Johnson AG, Martin J, Goldstein BJ, Shi Y:
Human epicardial adipose tissue is a source of inflammatory mediators.
Circulation 2003, 108:2460-2466.
29. Bambace C, Telesca M, Zoico E, Sepe A, Olioso D, Rossi A, Corzato F, Di
Francesco V, Mazzucco A, Santini F, Zamboni M: Adiponectin gene
expression and adipocyte diameter: a comparison between epicardial
and subcutaneous adipose tissue in men. Cardiovasc Pathol 2011, 20:
e153-e156.
30. Roh SG, Song SH, Choi KC, Katoh K, Wittamer V, Parmentier M, Sasaki S:
Chemerin-a new adipokine that modulates adipogenesis via its own
receptor. Biochem Biophys Res Commun 2007, 362:1013-1018.
doi:10.1186/1475-2840-10-87
Cite this article as: Gao et al.: Association of chemerin mRNA expression
in human epicardial adipose tissue with coronary atherosclerosis.
Cardiovascular Diabetology 2011 10:87.
Gao et al. Cardiovascular Diabetology 2011, 10:87
http://www.cardiab.com/content/10/1/87
Page 9 of 9